Endocrine Abstracts

Introduction: Previously published UK Cancer Registry data showed incidence of Neuroendocrine Neoplasms rising between 2001 and 2015. This was higher than had been thought (Genus et al.). We report more recent data with more accurate coding (ICD-O-3).Aim: To analyse National Cancer Registration and Analysis Service (NCRAS) data on Neuroendocrine Neoplasias (NENs) in England including years 2015–2017.Methods: Public He...

Introduction: Incidence of neuroendocrine neoplasia (NEN) is rising worldwide. The National Cancer Registry and Analysis Service allows accurate study of NEN in England. Aim: Calculate incidence and prevalence of NEN in England from 1995-2018. Calculate site-specific survival with multivariate analysis. Method: A population-based retrospective cohort study was performed. Data requested from NCRAS were reviewed by a steering group r...

Introduction: Sex differences have been noted at different sites of Neuroendocrine Neoplasia in previous registry studies across different countries. Analysis of National Cancer Registry and Analysis Service (NCRAS) data can help to clarify the significance and importance of this factor in England. Aim: To examine neuroendocrine neoplasia incidence and survival by sex, site and stage. Method: A population-based, cohort study was pe...

Background: Patients with neuroendocrine neoplasms (NENs) may often develop other malignancies. This study aimed to identify the frequency at which these second non-NEN malignancies occurred in England.Methods: Data was extracted from the National Cancer Registration and Analysis Service (NCRAS) on all patients diagnosed with a NEN at one of eight NEN site groups between 2012-2018: appendix, caecum, colon, lung, pancreas, rectum, small intestine and stom...

Introduction: Historically the incidence and prevalence of neuroendocrine tumours (NETs) has been difficult to establish due to issues with disease coding and data collection. Studies estimated the incidence of gastroenteropancreatic neuroendocrine tumours (GEP NETs) to be 1.3 per 100,000 per year (incidence hereafter given as cases per 100,000). However, the SEER USA data suggests a four-fold higher incidence, and prevalence of 35 per 100,000. This study aimed to identify the...

Introduction: Accurate survival data for patients with neuroendocrine tumours (NETs) across the UK has been difficult to capture. Individual centres often report good survival rates, however, national data has not previously been available.Materials and methods: NET patient survival was calculated for England using the Public Health England (PHE) National Cancer Registration and Analysis Service (NCRAS) dataset which captures tumour stage using TNM stagi...

Introduction: Historically there has been an association with neuroendocrine tumours (NETs) and other cancers. However, this has not previously been well characterised. We aimed to determine the incidence of second malignancies in patients with NETs and investigate any association of the anatomical site of NETs with other malignancies.Materials and methods: 12,844 patients were diagnosed with a NET between 2013 and 2015 and captured by the National Cance...